Towards artificial intelligence-driven pathology assessment for hematological malignancies

Olivier Elemento, PhD
Caryl and Israel Englander Institute for Precision Medicine
Weill Cornell Medicine
New York, NY, 10021

In this issue of Blood Cancer Discovery, Brück et al applied unsupervised and supervised machine learning to bone marrow histopathology images from Myelodysplastic Syndrome (MDS) patients. Their study provides new insights into the pathobiology of MDS and paves the way for increased use of artificial intelligence for the assessment and diagnosis of hematological malignancies.

Myelodysplastic syndrome (MDS) is a group of hematological disorders characterized by ineffective and dysplastic hematopoiesis in the bone marrow. For decades, the diagnosis of MDS has relied almost solely on visual morphologic analysis of stained bone marrow samples, involving assessment of cellular dysplasia, blast count, cellularity, monocytes, ring sideroblasts and a few other features. MDS have been further classified into subtypes based on the World Health Organization (WHO) classification scheme, which combines morphology with blood count and cytogenetics. The number and complexity of features used for diagnosis and the subjectivity of their assessment can make a precise diagnosis difficult to achieve in some cases, even for the highly trained hematopathologist. As a result, bone marrow assessments are known to be associated with substantial inter-pathologist variability. More recently, genomic analysis of MDS has allowed for further characterization of MDS cells. A number of frequently mutated genes were identified, e.g. TET2, ASXL1, SF3B1, SRSF2, DNMT3A and RUNX1. With a few exceptions such as the megakaryocyte dysmorphology in 5q-deleted MDS or presence of ring sideroblasts in SF3B1-mutated MDS, the relationship between morphology and mutations remains poorly characterized. This is unfortunate, since the concordance between normally correlated features can reinforce the confidence in each individual feature and may contribute to enhancing diagnostic accuracy.

Can machine learning (ML, a form of artificial intelligence or AI) and automated image analysis provide additional insights for MDS? This is the problem that Brück et al. sought to address in this issue of Blood Cancer Discovery. Histopathology slides are now routinely digitized and therefore amenable to automated or semi-automated image analysis. Large datasets combining these images with genomic and clinical information are being collected at a number of medical centers. In other malignancies, the application of ML to histopathology slides has been shown to provide diagnostic and prognostic accuracy on par with trained diagnosticians. For example, ML can diagnose skin malignancies from digital images with performance rivaling trained dermatologists. ML can also distinguish accurately between select subtypes of cancers, predict prognosis in mesothelioma and even predict the presence of specific mutations e.g. EGFR in lung adenocarcinomas.

Brück et al leveraged some relatively recent key developments in the field of machine learning applied to images. One of them is called transfer learning. Transfer learning refers to the re-utilization of deep neural networks that have already been trained to recognize a multitude of non-medical images and objects from huge image databases such as the well-known ImageNet.
By mimicking the way the human visual cortex works, these networks have learned
to recognize basic image features such as shapes and textures. These features are encoded
within the networks during training, a lengthy process that takes supercomputers and gigantic
databases such as ImageNet to achieve successfully. Once a network is trained, new images,
including pathology images, can be entered as input and propagated through the network. The
network features that are activated (much in the same way that neurons are activated) during
this process can be recorded. Thus a pathology image can be described by all the internal
features that are activated in a pre-trained neural network.

There remain many obstacles to applying these pre-trained neural networks to pathology
images. One is that entire slides of variable and sometimes large sizes cannot typically be
directly used as input to trained network. Instead, digitized slides have to be split into smaller
and uniformly sized tiles. This is a limitation as tiles need to somehow be combined but also an
opportunity to capture intra-tissue heterogeneity. Moreover, the pre-trained network features are
automatically generated and not selected based on prior knowledge of bone marrow
morphology. To make them interpretable for a trained hematopathologist, they must be
decoded.

Brück et al analyzed bone marrow samples from 143 MDS patients; 51 patients with
myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and 11 control subjects. In total 500
tiles were analyzed. Upon extracting features using the widely used VGG16 and Xception
convolutional neural networks (CNNs), Brück et al performed an unsupervised analysis by
mapping each tile onto a two-dimensional space using the Uniform Manifold Approximation and
Projection (UMAP) technique, most frequently used for analyzing single cell transcriptomic data.
In this representation, tiles with similar image feature profiles are located close to each on the
two-dimensional space. Five clusters emerged and visual analysis of tiles within each cluster
shed light on their content. These clusters captured high abundance of lipid droplets, red blood
cells, stroma, hypocellular and hypercellular tiles. This served as validation that the deep
learning-extracted features do in fact reflect biologically relevant features, a non-negligible
observation given the fact that the CNNs were trained on ImageNet, a database that contains
few if any histopathological images. Brück et al then averaged feature profiles for tiles belonging
to the same sample, then reprojected the samples in two dimensions using UMAP, followed by
unsupervised clustering. Five clusters emerged again. Healthy subjects formed
a distinct cluster
and were not only homogenous but also highly distinguishable from the four MDS clusters. Each
of the four clusters were enriched in specific MDS WHO subtypes. However, MDS sample
groupings only partially overlapped with the WHO subtypes. This is not unexpected since WHO
subtypes are defined not only by bone marrow cytomorphology but also by cytogenetics, blast
proportion and blood cell counts.

Brück et al then moved on to supervised analyses, seeking to train statistical models based on
elastic net regularized regression to predict a variety of tumor and patient characteristics based
on image features. Certain characteristics such as mutations in TET2, ASXL1, and STAG2,
chromosome 7 monosomy, and 7q deletion turned out to be highly predictable from
morphological features. This demonstrates that the links between morphological features and
mutations is more extensive than previously thought in MDS. Brück et al were also able to
predict the risk stratifying IPSS-R score (Revised International Prognostic Scoring System),
overall survival and progression to Acute Myeloid Leukemia (AML) with high accuracy by solely
employing features extracted from stained slides. Strikingly, progression to AML was best
predicted using a model that combined histopathology features and conventional IPSS-R
scores. A model was able to discern MDS patients from MDS/MPN patients with an accuracy of
0.81 (1.0 being the maximum achievable accuracy). Analysis of direct cell and image segmentation and classification showed as expected, that predicted MDS samples were hypoplastic with higher stromal involvement.

This is not the first time that machine learning has been used to assess MDS. For example, Nagata et al successfully used morphological features from pathology reports to predict mutational profiles. Mori et al were able to accurately assess dysplasia in bone marrow smear using a convolutional neural network. Brück et al demonstrate how much the field of AI has advanced in the past few years, especially the concept of transfer learning. One can now use off-the-shelf pre-trained deep neural networks and deploy them on a new medical image dataset of modest size (a few hundred images) without need for extensive retraining (which would take a much larger dataset to achieve).

Altogether Brück et al’s work represents an exciting step towards AI-driven pathological assessment in MDS and more generally in hematologic malignancies. Although not the central goal of Brück et al, their work clearly suggests that MDS can be distinguished from normal bone marrow with minimal to no ambiguity using ML. One would imagine that once extended to a larger dataset, validated with data from other independent centers, the AI behind Brück et al may be used to help improve or refine MDS diagnosis, especially in cases that are difficult to diagnose or classify using conventional methods. There may be additional applications for approaches like Brück et al. For example, the unbiased assessment that AI provides can also be used either in preclinical animal models or in clinical trials to assess the effect of investigational therapies on the bone marrow of MDS patients.

Despite the advances described in Brück et al and in many other recent papers applying AI to medical images, much work remains to be done to enable routine use of AI in pathology and other fields. AI models ideally need to be trained on diverse data from multiple medical centers in order to minimize biases associated with individual centers. Unfortunately, data sharing across medical centers remains infrequent and difficult due to competition between centers and sometimes unnecessary regulatory requirements. Prospective validation of AI models using randomized clinical trials remains too rare. One of the key barriers to adopting medical AI is the limited interpretability of AI models. By opting to use transfer learning instead of directly applying convolutional neural networks to pathology images, Brück et al’s approach has the advantage of generating features whose importance for classification can rather easily be assessed. That does not mean that they can readily be understood, even by a trained hematopathologist. As shown in Brück et al, these features need to be decoded. AI models also need to further integrate the complexity of tumors. For example, averaging feature profiles for the same sample as performed by Brück et al works but also loses information on potential intra-tumor heterogeneity. Such heterogeneity, if better captured, may help improve predictive models based on histopathology slides.

Will conventional morphological assessment and the ubiquitously applied WHO classification soon be replaced by artificial intelligence? Probably not, but Brück et al outlines an exciting future where cooperation between hematopathologists and AI improves the quality and depth of pathology assessments for MDS and other malignancies.

References


Towards artificial intelligence-driven pathology assessment for hematological malignancies

Olivier Elemento

Blood Cancer Discov  Published OnlineFirst March 22, 2021.

Updated version  Access the most recent version of this article at: doi: 10.1158/2643-3230.BCD-21-0048

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://bloodcancerdiscov.aacrjournals.org/content/early/2021/03/19/2643-3230.BCD-21-0048. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.